Last updated: February 14, 2026
Summary
NDC 68084-0729 corresponds to Pretomanid, a drug approved by the FDA in 2019 for treating extensively drug-resistant (XDR) tuberculosis (TB). The drug's market largely depends on tuberculosis treatment protocols, regulatory factors, manufacturing capacity, and competition from existing therapies.
What Is the Current Market Landscape for Pretomanid?
Pretomanid is part of combination regimens approved under the BLA (Biologics License Application) 761124, mainly in combination with bedaquiline and linezolid. Its primary market involves hospital and specialty pharmacies focusing on resistant TB treatment.
Regulatory status and indications:
- FDA approval date: August 13, 2019
- Indications: Treatment of certain forms of resistant TB, specifically XDR TB.
- Orphan drug designation: Yes, which influences pricing and market exclusivity policies.
Manufacturing and supply considerations:
- Manufacturers: The drug is developed by the Drugs for Neglected Diseases Initiative (DNDi) with support from Johnson & Johnson.
- Supply chain: Limited due to complex synthesis and focused production centers, which constrains immediate volume expansion.
Market size:
- Global TB cases (2021): Approx. 10 million cases (WHO)
- Resistant TB proportion: 3-5% of cases are resistant, roughly 300,000 cases globally.
- US-specific: Few cases are resistant variants, limiting the immediate domestic market.
Competitive Landscape
- Existing therapies: Novel drug formulations for resistant TB are sparse.
- Alternatives: Linezolid, bedaquiline, levofloxacin, and other second-line TB drugs.
- Market differentiators for Pretomanid: Its use in combination therapies specifically for resistant strains distinguishes its niche.
Pricing Analysis
Current pricing:
- Wholesale acquisition cost (WAC): Estimated at around $3,500 to $4,200 per treatment course. This is based on initial pricing model; actual prices differ across payers.
Cost factors:
- Combination use: Typically administered with other drugs, influencing overall therapy costs.
- Pricing trends: Reflects high costs for resistant TB drugs, often supported by government programs and subsidies.
- Pricing constraints: The orphan drug status supports premium pricing but limits volume.
Pricing benchmarks:
| Drug |
Price per course (Estimate) |
Notes |
| Pretomanid (NDC: 68084-0729) |
$3,500 - $4,200 |
Based on proprietary and specialty pricing strategies |
| Bedaquiline (Sirturo) |
~$30,000 annually |
For resistant TB, but not directly comparable due to different indications |
| Linezolid (Zyvox) |
~$3,000 for a 14-day course |
Used in combination therapy |
Price Projections
Near-term (1-2 years):
- Prices likely remain steady around current levels due to limited global and U.S. supply channels.
- Price adjustments may occur with increased competition from generics or biosimilars if patent protections lapse or stewardship policies shift.
Medium-term (3-5 years):
- Price reductions are possible if generic manufacturing enters the market or if alternative therapies reduce dependence on Pretomanid.
- Price increases could happen if resistance patterns evolve, requiring higher doses or more complex regimens.
Long-term (>5 years):
- Integrated market expansion depends on broader adoption, new combinations, and regulatory approvals for alternative indications.
- Price stabilization at high levels if the drug maintains a market monopoly due to regulatory exclusivity.
Regulatory and Policy Influences
- Orphan drug exclusivity (7 years): Protects against generic entry until at least 2026.
- Government programs: Large-scale procurement by the Global Fund, CDC, and other agencies sustain premium pricing.
- Patent landscape: Patent filings and potential litigation affect lifecycle and pricing strategies.
Market Entry and Growth Opportunities
- Broader application for other resistant bacteria or latent TB treatment could open new markets.
- Regenerative approaches or combination therapies may influence future pricing structures.
- Expansion in low- and middle-income countries hinges on differential pricing models and subsidy programs.
Key Takeaways
- Pretomanid (NDC 68084-0729) remains a niche but critical therapy for resistant TB.
- Current pricing resides around $3,500–$4,200 per treatment course, supported by orphan drug protections and specialty healthcare markets.
- Medium-term projections suggest price stability unless patent expiry, generic entry, or policy shifts occur.
- The global TB market's size and resistance patterns heavily influence manufacturing and pricing strategies.
- Payers and governments predominantly absorb costs, which buffers immediate declines but limits profitability.
FAQs
1. How does Pretomanid compare price-wise to other TB drugs?
Pretomanid’s per-course cost is comparable to drugs like linezolid (~$3,000), but significantly lower than newer drugs like bedaquiline (~$30,000 annually). Its pricing reflects its niche in resistant TB treatment.
2. What factors could cause Pretomanid prices to decline in the future?
Introduction of generics, patent expiration, or alternative, more cost-effective therapies could lower prices. Policy shifts favoring generic access can also influence pricing.
3. Are there any upcoming regulatory changes that could affect Pretomanid's pricing?
Potential patent challenges or regulatory approvals for new indications may impact market exclusivity and pricing structures.
4. How does global TB burden affect Pretomanid's market?
Limited TB resistance cases restrict volume. Increased resistance prevalence or expanded indication approvals could expand the market and influence pricing.
5. What role do government and non-profit programs play?
They support access through subsidies, bulk purchasing, and donation programs, which stabilize or limit the achievable price point in many markets.
Citations
[1] World Health Organization. Global Tuberculosis Report 2022.
[2] FDA. Approved Drugs for TB. August 2019.
[3] Johnson & Johnson. Bedaquiline Pricing and Market Data.
[4] National Institute of Allergy and Infectious Diseases. TB Resistance Trends.
[5] IQVIA. Pharmaceutical Pricing Data, 2022.
